Medrano Chloé, Cointault Olivier, Lavayssiere Laurence, Nogier Marie-Béatrice, Colliou Eloïse, Setbon Nicolas, Kamar Nassim, Faguer Stanislas
Département de Néphrologie et Transplantation d'Organes, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Clin Kidney J. 2021 Apr 28;14(12):2534-2538. doi: 10.1093/ckj/sfab087. eCollection 2021 Dec.
There is an unmet need to develop safe and successful heparin-free regional anticoagulation modalities in haemodialysed patients at risk of bleeding. Whether the addition of citrate as a prefilter injection or in the dialysate itself is required to reach anticoagulation objectives when calcium-free dialysate is used as regional anticoagulation remains unclear.
In this monocentric retrospective study, we report our experience of 908 dialysis sessions performed with a calcium-free citrate-containing dialysate and calcium reinjection according to the ionic dialysance, without additional heparin.
Premature termination for filter clotting occurred in 20 sessions (2.2%) and duration of session was >4.5 h in 135 (15%; maximum duration 6 h). In addition, we could investigate the citrate, calcium and acid-basis status during haemodialysis sessions performed with (citrate group, = 20 sessions) or without (citrate-free group, = 19 sessions) citrate in the dialysate. In 20 sessions performed in patients with underlying liver disorders and using calcium-free citrate-containing dialysate, patients' ionized calcium (iCa) and serum citrate levels were stable and remained within the normal range, respectively. Post-filter iCa was below 0.4 mmol/L in 19/20 sessions and citrate was 0.304 mmol/L (range: 0.011; 0.548). In 19 sessions that used calcium and citrate-free dialysate, post-filter iCa was 0.41 mmol/L (0.34; 0.5) and all sessions extended to 4 h or beyond.
Regional anticoagulation of haemodialysis with a calcium-free dialysate and calcium reinjection according to the ionic dialysance is safe. Adding citrate to the dialysate is not mandatory to prevent dialysis circuit clotting in most patients.
对于有出血风险的血液透析患者,开发安全且成功的无肝素局部抗凝方式存在未满足的需求。当使用无钙透析液进行局部抗凝时,是否需要添加柠檬酸盐作为滤器前注射剂或添加到透析液本身以达到抗凝目标仍不清楚。
在这项单中心回顾性研究中,我们报告了908次透析治疗的经验,这些治疗使用了含无钙柠檬酸盐的透析液,并根据离子透析率进行钙再注射,未额外使用肝素。
20次治疗(2.2%)因滤器凝血而提前终止,135次治疗(15%;最长持续时间6小时)的治疗时间>4.5小时。此外,我们可以研究在透析液中添加(柠檬酸盐组,n = 20次治疗)或不添加(无柠檬酸盐组,n = 19次治疗)柠檬酸盐的血液透析治疗过程中的柠檬酸盐、钙和酸碱状态。在20次对有潜在肝脏疾病的患者进行的治疗中,使用含无钙柠檬酸盐的透析液,患者的离子钙(iCa)和血清柠檬酸盐水平分别保持稳定且在正常范围内。在19/20次治疗中,滤器后iCa低于0.4 mmol/L,柠檬酸盐为0.304 mmol/L(范围:0.011;0.548)。在19次使用无钙和无柠檬酸盐透析液的治疗中,滤器后iCa为0.41 mmol/L(0.34;0.5),所有治疗均延长至4小时或更长时间。
根据离子透析率使用无钙透析液和钙再注射进行血液透析的局部抗凝是安全的。在大多数患者中,向透析液中添加柠檬酸盐并非防止透析回路凝血所必需。